We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Back
Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
by Asger Wretlind, Andressa de Zawadzki, Rasmus Sejersten Ripa, Viktor Rotbain Curovic, Bernt Johan von Scholten, Ismo Matias Mattila, Tine Willum Hansen, Andreas Kjær, Peter Rossing, Cristina Legido-Quigley
Abstract:
Background: Liraglutide is a glucose-lowering medication used to treat type 2 diabetes and obesity. It is a GLP-1 receptor agonist with downstream metabolic changes beyond the incretin system, such as reducing the risk of cardiovascular complications. The understanding of these changes is critical for improving treatment outcomes. Herein, we present a post hoc experimental analysis using metabolomic phenotyping to discover molecular mecphanisms in response to liraglutide.